BROSHY ERAN 4
4 · Theravance Biopharma, Inc. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
BROSHY ERAN
Director
Transactions
- Sale
Ordinary Shares
2025-11-26$20.00/sh−14,000$280,000→ 60,204 total - Sale
Ordinary Shares
2025-11-26$20.00/sh−15,501$310,020→ 44,703 total - Exercise/Conversion
Share Option (Right to Buy)
2025-11-26$10.15/sh+14,000$142,100→ 81,749 totalExercise: $10.15Exp: 2032-04-25→ Ordinary Shares (14,000 underlying)
Footnotes (4)
- [F1]The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
- [F2]The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
- [F3]This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).
- [F4]Reflects solely exercisable, vested Share Options following reported transaction.